ViaCyte, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Cythera, Inc. (to 2012)
Previously recorded as Novocell, Inc. (to 2011)
72
Ending by 2030
Feb 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 30, 2026The maintenance fee for Cryopreserved in vitro cell culture of human pancreatic progenitor cells (US 11,660,377) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
- 1 fee due Dec 2, 2026The maintenance fee for Methods for enriching for pancreatic endocrine cells (US 9,045,736) comes due Dec 2, 2026. Unpaid by Jun 2, 2027, it lapses early.
- 4 fees due Feb 6 to 27, 2027 · next Feb 6
- 1 fee due Mar 15, 2027The maintenance fee for Encapsulation of pancreatic cells derived from human pluripotent stem cells (US 9,132,226) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
- 3 fees due Aug 13 to 20, 2027 · next Aug 13
- 2 fees due Sep 5 to 12, 2027 · next Sep 5
Recent changes
- 2 of the patents on this record were granted since Aug 16, 2026
- 4 terms have ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,415,158 | Compositions and methods useful for culturing differentiable cells In force · From the USPTO record | In force | From the USPTO record | |
| US 8,658,352 | Compositions and methods useful for culturing differentiable cells In force · From the USPTO record | In force | From the USPTO record | |
| US 8,633,024 | PDX1 expressing endoderm In force · From the USPTO record | In force | From the USPTO record | |
| US 7,534,608 | Methods of producing pancreatic hormones In force · From the USPTO record | In force | From the USPTO record | |
| US 7,993,920 | Methods of producing pancreatic hormones In force · From the USPTO record | In force | From the USPTO record | |
| US 8,603,811 | Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production In force · From the USPTO record | In force | From the USPTO record | |
| US 10,517,901 | Methods of lowering blood glucose levels in a mammal In force · From the USPTO record | In force | From the USPTO record | |
| US 8,586,357 | Markers of definitive endoderm In force · From the USPTO record | In force | From the USPTO record | |
| US 9,980,986 | Methods of producing pancreatic hormones In force · From the USPTO record | In force | From the USPTO record | |
| US 8,574,905 | Hepatocyte lineage cells In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 100: 9 lapsed for an unpaid fee · 14 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
9 pending · 4 abandoned · 20 no status recorded